Solutions to support your pipeline

As the world's leading clinical research organisation, ICON drives flexibility and operational efficiency.  ICON delivers full-service, FSP, and blended outsourcing approaches, for cost savings, access to specialised expertise, and greater control over operations amidst increasing trial complexity.
 

The way the industry outsources is evolving to maximise ROI and efficiency amid increasing complexity and difficulty within the clinical development landscape. The rise of more strategic partnerships and sponsors’ reassessment of their requirements have contributed to the uptick in blended outsourcing models, allowing sponsors to take advantage of best-fit solutions to optimise their programs.

Decentralised and hybrid trials bring a range of benefits to the patient and the sponsor. However, every study needs to be assessed for suitability and requires a framework based on a range of different aspects and considerations. ICON can guide you through the choices and provide support to develop a solution that works specifically for your study.

ICON is currently deploying decentralised and hybrid clinical trials on a global basis in multiple therapeutic areas and will support you in navigating the assessment, planning and execution.

The ICON digital platform captures, curates and consumes data for integrated decentralised clinical trials. ICON has applied its experience to develop this built-for-purpose platform hosted securely on Microsoft Azure. API-first technology is used to enable an efficient configuration and integration of clinical trial data. The platform is modular, configurable, scalable and meets compliance and regulatory standards such as 21 CRF Part 11.

Accellacare, ICON's clinical research network, provides greater access to patients and multi-specialty physicians. This network of research sites offers proven support and infrastructure for your clinical research.

You will benefit from increased patient access, quicker start-up, consitent and centralised training programs to ensure quality and compliance, and a detailed site and patient burden assessment to optimise the study protocol for greatest efficiency.

ICON is the only full-service, ISO 17100 and ISO 9001 certified translation provider within a global top-tier CRO, offering total harmonisation between product development processes and translation methodology. 

We have flexible scalability with a global network of over 2,500 trusted medical and clinical translators, including linguistic validation specialists, covering over 300 languages across every location where clinical research takes place.

ICON Language Services operates independently as a translation provider, leveraging the knowledge and expertise of our ICON clinical research colleagues. Our comprehensive clinical glossaries are developed jointly by experts in clinical research and linguistics fields. Our team has up to date and in-depth industry knowledge of country-specific regulations, global markets and the full drug development process.

ICON delivers a comprehensive and adaptable eCOA solution spanning protocol design to study closeout. Our experts will work with you from consultancy support to design and review your eCOA strategy, through licensing and early eCOA assessment, in conjunction with Mapi Research Trust, to linguistic validation, deployment and user acceptance testing.

Read our recent whitepaper, "Keeping eCOA implementation off a trial's critical path" for a best-practice approach.

We understand the unique challenges and complexities that patients with a rare condition face generally and in clinical research studies, compared to those in more common indications. By maintaining focus on the patient, their family, and their quality of life, we can anticipate and mitigate risks, and efficiently conduct rare disease studies. ICON can help you optimise the whole continuum of the clinical trial lifecycle, from patient enrolment to payer reimbursement. Our experienced clinical and therapeutic teams have conducted hundreds of rare disease trials across a wide range of therapeutic areas.

ICON's Rare and Orphan Diseases team provides analysis including whitepapers, blogs and contributions to media and industry conversations relating to all aspects of rare and orphan diseases in clinical trials.

We recognise that access to adequate healthcare is a fundamental human right. Across the world, we’ve engaged an ever-growing number of clinical trial investigators and built long-lasting relationships with customers. By working together, we’ve made a measurable difference to improve the lives of patients.

At its core, ICON’s mission is to improve health and lives. ICON Cares brings together all our Environment, Social and Governance (ESG), Diversity, Inclusion and Belonging (DIB) and Corporate Social Responsibility (CSR) initiatives under one umbrella. It is a pledge to achieve more together. As a company of over 41,000 people working across more than 50 countries, we have an enormous opportunity to put our expertise, experience and human kindness into action as a force for good.